<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">76495</article-id><article-id pub-id-type="doi">10.7554/eLife.76495</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Cross-species analysis of LZTR1 loss-of-function mutants demonstrates dependency to RIT1 orthologs</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-265202"><name><surname>Cuevas-Navarro</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-265203"><name><surname>Rodriguez-Muñoz</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-149588"><name><surname>Grego-Bessa</surname><given-names>Joaquim</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0938-2346</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-265204"><name><surname>Cheng</surname><given-names>Alice</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-265205"><name><surname>Rauen</surname><given-names>Katherine A</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-6530"><name><surname>Urisman</surname><given-names>Anatoly</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8364-5303</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-141626"><name><surname>McCormick</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-56213"><name><surname>Jimenez</surname><given-names>Gerardo</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-264650"><name><surname>Castel</surname><given-names>Pau</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4972-4347</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><institution content-type="dept">Helen Diller Family Comprehensive Cancer Center</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Institute for Molecular Biology of Barcelona</institution>, <institution>Consejo Superior de Investigaciones Científicas</institution>, <addr-line><named-content content-type="city">Barcelona</named-content></addr-line>, <country>Spain</country></aff><aff id="aff3"><institution content-type="dept">Intercellular Signalling in Cardiovascular Development and Disease Laboratory</institution>, <institution>Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)</institution>, <addr-line><named-content content-type="city">Madrid</named-content></addr-line>, <country>Spain</country></aff><aff id="aff4"><institution content-type="dept">MIND Institute</institution>, <institution>University of California, Davis</institution>, <addr-line><named-content content-type="city">Sacramento</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Department of Anatomic Pathology</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Department of Biochemistry and Molecular Pharmacology</institution>, <institution>New York University</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-216505"><name><surname>Berger</surname><given-names>Alice</given-names></name><role>Reviewing editor</role><aff/></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>pau.castel@nyulangone.org</email> (PC);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>25</day><month>04</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e76495</elocation-id><history><date date-type="received"><day>17</day><month>12</month><year>2021</year></date><date date-type="accepted"><day>22</day><month>04</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, Cuevas-Navarro et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Cuevas-Navarro et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-76495-v1.pdf"/><abstract><p>RAS GTPases are highly conserved proteins involved in the regulation of mitogenic signaling. We have previously described a novel Cullin 3 RING E3 ubiquitin ligase complex formed by the substrate adaptor protein LZTR1 that binds, ubiquitinates, and promotes proteasomal degradation of the RAS GTPase RIT1. In addition, others have described that this complex is also responsible for the ubiquitination of classical RAS GTPases. Here, we have analyzed the phenotypes of <italic>Lztr1</italic> loss-of-function mutants in both fruit flies and mice and have demonstrated a biochemical preference for their RIT1 orthologs. Moreover, we show that <italic>Lztr1</italic> is haplosufficient in mice and that embryonic lethality of the homozygous null allele can be rescued by deletion of <italic>Rit1</italic>. Overall, our results indicate that, in model organisms, RIT1 orthologs are the preferred substrates of LZTR1.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>D. melanogaster</italic></kwd><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>F31CA265066</award-id><principal-award-recipient><name><surname>Cuevas-Navarro</surname><given-names>Antonio</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R35CA197709</award-id><principal-award-recipient><name><surname>McCormick</surname><given-names>Frank</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R00CA245122</award-id><principal-award-recipient><name><surname>Castel</surname><given-names>Pau</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>DOD CDMRP Neurofibromatosis Research Program</institution></institution-wrap></funding-source><award-id>W81XWH-20-1-0391</award-id><principal-award-recipient><name><surname>Castel</surname><given-names>Pau</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Frank McCormick, is a consultant for Ideaya Biosciences, Kura Oncology, Leidos Biomedical Research, Pfizer, Daiichi Sankyo, Amgen, PMV Pharma, OPNA-IO, and Quanta Therapeutics and has received research grants from Boehringer-Ingelheim and is a consultant for and cofounder of BridgeBio Pharma..</p></fn><fn fn-type="conflict" id="conf3"><p>Pau Castel, PC is a founder and advisory board of Venthera..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#AN165444 and #AN179937) of the University of California San Francisco.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for all Figures.</p></sec><supplementary-material><ext-link xlink:href="elife-76495-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>